The Beauty Health Company announced its financial results for the fourth quarter and full year ended December 31, 2024, on March 12, 2025. For the full year 2024, total net revenue reached $334.29 million, and adjusted EBITDA was $12.3 million, both exceeding prior guidance.
The company achieved a significant improvement in its full-year 2024 GAAP gross margin, rising to 54.5% from 39% in 2023, primarily due to the absence of large inventory write-downs and a favorable mix shift. Operating expenses were reduced by over $30 million year-over-year in 2024, demonstrating increased financial discipline.
In the fourth quarter of 2024, BeautyHealth delivered $9 million of adjusted EBITDA, exceeding the high end of its guidance. The active install base grew to 34,735 units, up from 31,446 in the prior year, contributing to growth in consumable net sales.
For the full year 2025, the company projects net sales between $270 million and $300 million and adjusted EBITDA between $15 million and $25 million. This guidance assumes continued pressure on delivery systems across all regions and incorporates an estimated $5 million of additional cost due to tariffs.
The company also completed the consolidation of global manufacturing operations to its U.S. facility in Q4 2024 and plans to convert its China market from a direct sales to a distributor model in 2025. These strategic shifts aim to enhance quality control, increase agility, and improve long-term profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.